''On separate “subscales” measuring positive or negative symptoms, KarXT was also superior to placebo. KarXT-treated patients had a reduction of nearly 7 points compared with about 4 points in the placebo group. Negative symptoms declined 3.4 points in the KarXT group vs. 1.6 points in the placebo group.‘’
''Side effects were present, as they are with virtually all medications, but were considered comparatively mild to moderate by the researchers. The most common were constipation, dyspepsia, headache, and nausea. Importantly, KarXT “was not associated with many of the adverse events typically associated with current antipsychotic treatments including extrapyramidal motor symptoms, weight gain, changes in lipid and glucose parameters, prolactin elevation/sexual dysfunction and somnolence.”
